National Institute on Drug Abuse; Notice of Closed Meeting, 59389-59390 [2018-25426]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 226 / Friday, November 23, 2018 / Notices
Public attendance at the meeting is
limited to the available space.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Advisory Council at the
address/telephone number listed above
at least one week prior to the meeting.
For those unable to attend in person, a
live webcast will be available. More
information on registration and
accessing the webcast can be found at
https://www.hhs.gov/ash/carb/.
Members of the public will have the
opportunity to provide comments prior
to the Advisory Council meeting by
emailing CARB@hhs.gov. Public
comments should be sent in by
midnight January 23, 2019, and should
be limited to no more than one page. All
public comments received prior to
January 23, 2019, will be provided to
Advisory Council members; comments
are limited to five minutes per speaker.
Dated: November 16, 2018.
Tammy R. Beckham,
Acting Director, National Vaccine Program
Office.
[FR Doc. 2018–25439 Filed 11–21–18; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
amozie on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Research Education Program for Clinical
Researchers and Clinicians (R25).
Date: November 27, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
VerDate Sep<11>2014
18:33 Nov 21, 2018
Jkt 247001
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; MultiSite Studies for System-Level
Implementation of Substance Use Prevention
and Treatment Services (R01; R34).
Date: November 27, 2018.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Workshops on the Use of Adolescent Brain
Cognitive Development (ABCD) Data (R25
Clinical Trial Not Allowed).
Date: November 29, 2018.
Time: 10:00 a.m. to 11:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research (R21 Clinical Trial Optional).
Date: December 5, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
59389
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Exceptional Research on HIV/
AIDS and Substance Abuse (R01, Clinical
Trial Optional).
Date: December 13, 2018.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25427 Filed 11–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Pharmacokinetic Analysis Resource Center
(8947).
Date: January 8, 2019.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
E:\FR\FM\23NON1.SGM
23NON1
59390
Federal Register / Vol. 83, No. 226 / Friday, November 23, 2018 / Notices
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 827–5702, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: November 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25426 Filed 11–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
amozie on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Informatics Methodology
and Secondary Analyses for Immunology
Data in ImmPort.
Date: December 14, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Paul A. Amstad, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G41, 5601 Fishers Lane, Bethesda,
MD 20892–7616, 240–669–5067, pamstad@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Sep<11>2014
18:33 Nov 21, 2018
Jkt 247001
Dated: November 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25428 Filed 11–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning the
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer at (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: Substance Abuse
Prevention and Treatment Block Grant
Synar Report Format, FFY 2020–2022—
(OMB No. 0930–0222)—Extension
Section 1926 of the Public Health
Service Act [42 U.S.C. 300x–26]
stipulates that Substance Abuse
Prevention and Treatment Block Grant
(SABG) funding agreements for alcohol
and drug abuse programs for fiscal year
1994 and subsequent fiscal years require
states to have in effect a law stating that
it is unlawful for any manufacturer,
retailer, or distributor of tobacco
products to sell or distribute any such
product to any individual under the age
of 18. This section further requires that
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
states conduct annual, random,
unannounced inspections to ensure
compliance with the law; that the state
submit annually a report describing the
results of the inspections, the activities
carried out by the state to enforce the
required law, the success the state has
achieved in reducing the availability of
tobacco products to individuals under
the age of 18, and the strategies to be
utilized by the state for enforcing such
law during the fiscal year for which the
grant is sought.
Before making an award to a state
under the SABG, the Secretary must
make a determination that the state has
maintained compliance with these
requirements. If a determination is made
that the state is not in compliance,
penalties shall be applied. Penalties
ranged from 10 percent of the Block
Grant in applicable year 1 (FFY 1997
SABG Applications) to 40 percent in
applicable year 4 (FFY 2000 SABG
Applications) and subsequent years.
Respondents include the 50 states, the
District of Columbia, the
Commonwealth of Puerto Rico, the U.S.
Virgin Islands, Guam, American Samoa,
the Commonwealth of the Northern
Mariana Islands, Palau, Micronesia, and
the Marshall Islands. Red Lake Indian
Tribe is not subject to tobacco
requirements.
Regulations that implement this
legislation are at 45 CFR 96.130, are
approved by OMB under control
number 0930–0163, and require that
each state submit an annual Synar
report to the Secretary describing their
progress in complying with section 1926
of the PHS Act. The Synar report, due
December 31 following the fiscal year
for which the state is reporting,
describes the results of the inspections
and the activities carried out by the state
to enforce the required law; the success
the state has achieved in reducing the
availability of tobacco products to
individuals under the age of 18; and the
strategies to be utilized by the state for
enforcing such law during the fiscal
year for which the grant is sought.
SAMHSA’s Center for Substance Abuse
Prevention will request an extension of
OMB approval of the current report
format associated with section 1926 (42
U.S.C. 300x–26) to 2022. Extending
OMB approval of the current report
format will continue to facilitate
consistent, credible, and efficient
monitoring of Synar compliance across
the states.
E:\FR\FM\23NON1.SGM
23NON1
]]>Agencies
[Federal Register Volume 83, Number 226 (Friday, November 23, 2018)]
[Notices]
[Pages 59389-59390]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25426]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Pharmacokinetic Analysis Resource Center (8947).
Date: January 8, 2019.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive
[[Page 59390]]
Boulevard, Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Lyle Furr, Scientific Review Officer, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: November 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25426 Filed 11-21-18; 8:45 am]
BILLING CODE 4140-01-P
